Based on the measurements of operating efficiency obtained from OmniAb's historical financial statements, OmniAb Inc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. As of now, OmniAb's Other Assets are increasing as compared to previous years. The OmniAb's current Non Current Liabilities Total is estimated to increase to about 49.4 M, while Total Assets are projected to decrease to under 364.9 M. Key indicators impacting OmniAb's financial strength include:
The essential information of the day-to-day investment outlook for OmniAb includes many different criteria found on its balance sheet. An individual investor should monitor OmniAb's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in OmniAb.
OmniAb competes with Legend Biotech, Verona Pharma, Ideaya Biosciences, Iteos Therapeutics, and Bioatla. OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company was founded in 2012 and is headquartered in Emeryville, California. Amniab operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining OmniAb's current stock value. Our valuation model uses many indicators to compare OmniAb value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across OmniAb competition to find correlations between indicators driving OmniAb's intrinsic value. More Info.
OmniAb Inc is regarded second in return on equity category among its peers. It is regarded third in return on asset category among its peers . As of now, OmniAb's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the OmniAb's earnings, one of the primary drivers of an investment's value.
OmniAb Inc Systematic Risk
OmniAb's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. OmniAb volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-five with a total number of output elements of sixteen. The Beta measures systematic risk based on how returns on OmniAb Inc correlated with the market. If Beta is less than 0 OmniAb generally moves in the opposite direction as compared to the market. If OmniAb Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one OmniAb Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of OmniAb is generally in the same direction as the market. If Beta > 1 OmniAb moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in OmniAb Stock are looking for potential investment opportunities by analyzing not only static indicators but also various OmniAb's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of OmniAb growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of OmniAb help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of OmniAb Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of OmniAb Inc based on widely used predictive technical indicators. In general, we focus on analyzing OmniAb Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build OmniAb's daily price indicators and compare them against related drivers.
When running OmniAb's price analysis, check to measure OmniAb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OmniAb is operating at the current time. Most of OmniAb's value examination focuses on studying past and present price action to predict the probability of OmniAb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OmniAb's price. Additionally, you may evaluate how the addition of OmniAb to your portfolios can decrease your overall portfolio volatility.